SCHEDULE: Fairmount Funds Management Discloses 19.99% Stake in Korsana Biosciences

Sentiment:

Schedule 13D Filing 11 September 2026 5:25 PM

📋All filings for Cyclerion Therapeutics, INC

Fairmount Funds Management LLC and its affiliates have disclosed a beneficial ownership of 19.99% in Korsana Biosciences, Inc. following a merger and financing.

Capital raiseThe filing references a 'Korsana Pre-Closing Financing' where investors, including Fund II and Co-Invest, agreed to purchase shares of Pre-Merger Korsana common stock or pre-funded warrants for an aggregate commitment of approximately $380.0 million.The acquisition of Series B Preferred Stock for $12,500,000 and Common Stock/Pre-Funded Warrants for $99,999,973 by the Reporting Persons also represents a capital investment.

Summary

Fairmount Funds Management LLC, along with its affiliates Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest VI L.P., has filed a Schedule 13D indicating beneficial ownership of 19.99% of Korsana Biosciences, Inc. common stock.
This ownership stake is a result of a merger completed on September 8, 2026, involving Korsana Biosciences, Inc. (formerly Pre-Merger Korsana) and the company's acquisition by Cyclerion Therapeutics, Inc. (which subsequently changed its name to Korsana Biosciences, Inc.).
The Reporting Persons' holdings include directly held shares of common stock and exclude shares issuable upon conversion of Series B Preferred Stock and exercise of Pre-Funded Warrants due to beneficial ownership limitations.
Tomas Kiselak, a managing member of Fairmount, serves as a director on the Korsana Biosciences board, potentially influencing corporate activities.
The filing details various agreements including a Merger Agreement, Articles of Amendment, Lock-up Agreements, a Subscription Agreement, and a Registration Rights Agreement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting significant strategic activity and investment, though with inherent complexities and potential future uncertainties.

Positives

Fairmount Funds Management has established a significant ownership position (19.99%) in Korsana Biosciences, indicating strong conviction in the company's future.
The merger and subsequent name change to Korsana Biosciences, Inc. represent a significant strategic step for the combined entity.
The company has secured substantial pre-closing financing of approximately $380.0 million through a Subscription Agreement.
The Series B Preferred Stock provides holders with significant governance rights, including the election of four directors with three votes each, and protective provisions against adverse changes.

Negatives

The beneficial ownership is capped at 19.99%, with specific limitations on the conversion of Series B Preferred Stock and exercise of Pre-Funded Warrants, preventing a higher stake without further action.
The Series B Preferred Stock conversion and Pre-Funded Warrant exercise are subject to beneficial ownership limitations, potentially restricting the full conversion of these securities.
Lock-up agreements are in place for 180 days post-merger, restricting the sale of securities for certain shareholders, including the Reporting Persons.

Risks

The beneficial ownership limitations (19.99%) on the conversion of Series B Preferred Stock and exercise of Pre-Funded Warrants could limit the Reporting Persons' ability to increase their stake or fully realize the value of these securities.
The company's name change and merger introduce integration risks and potential challenges in realizing the anticipated synergies.
The Series B Preferred Stock has specific voting rights and protective provisions that could lead to potential disagreements or governance complexities with common stockholders.
The lock-up agreements restrict the liquidity of a significant portion of the company's stock for 180 days, which could impact market dynamics upon their expiration.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance regarding future financial performance. However, the significant investment and strategic merger suggest a positive outlook from the Reporting Persons' perspective.

Management Comments

Fairmount serves as investment manager for Fund II and Co-Invest and may be deemed a beneficial owner of securities held by these entities.
Fund II and Co-Invest have delegated sole voting and disposal power to Fairmount and disclaim beneficial ownership for Section 13(d) purposes.
Mr. Kiselak serves as a member of the board of directors and may have influence over corporate activities.
Reporting Persons may review, reconsider, and change their position and/or develop plans at any time and may seek to influence management or the board.

Industry Context

StockSavvy.ai notes that this filing reflects a common strategy in the biotechnology and life sciences sector where investment firms like Fairmount Funds Management actively participate in financing and strategic transactions, including mergers and acquisitions, to consolidate or advance promising technologies. The structure of the Series B Preferred Stock with enhanced voting rights is also typical for significant investors seeking governance influence.

Comparison to Industry Standards

The 19.99% beneficial ownership threshold is a common limit in Schedule 13D filings, often chosen to avoid triggering certain regulatory requirements or to maintain flexibility.
The structure of Series B Preferred Stock with enhanced voting rights (e.g., 4 directors with 3 votes each) is a recognized mechanism for significant investors to ensure board representation and influence, seen in various venture capital and private equity investments in biotech.
The use of pre-funded warrants and convertible preferred stock with beneficial ownership limitations is a standard practice in financings to manage ownership percentages and regulatory compliance, particularly in the pharmaceutical and biotech industries.
The 180-day lock-up period is a typical duration for post-merger restrictions on insider stock sales, aligning with market practices to ensure stability following significant corporate events.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	Holders of Series B Preferred Stock are entitled to elect four directors ('Preferred Directors') who will each have three votes on board matters, as long as at least 30% of the originally issued Series B Preferred Stock remains outstanding.	Immediately prior to the effective time of the Second Merger	Significantly enhances the governance influence of Series B Preferred Stock holders, including the Reporting Persons, over board decisions.
Voting Rights	Series B Preferred Stock holders vote as a separate class for Preferred Directors. Common stock holders and other voting shares vote together as a single class for the remaining directors.	Immediately prior to the effective time of the Second Merger	Creates a dual-class voting structure for board elections, potentially leading to different interests between preferred and common stockholders.
Protective Provisions	Company cannot take certain actions (e.g., alter Series B Preferred Stock rights, issue more Series B, consummate a Fundamental Transaction, increase board size) without the affirmative vote of a majority of the Series B Preferred Stock holders.	As long as any Series B Preferred Stock are outstanding	Provides strong veto power to Series B Preferred Stock holders over critical corporate actions, safeguarding their investment.

Related Party Transactions

Fairmount Funds Management LLC acts as the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest VI L.P., entities holding significant stakes in Korsana Biosciences.
Tomas Kiselak, a managing member of Fairmount, serves as a director on the board of Korsana Biosciences.
The Reporting Persons are subject to lock-up agreements, which are standard arrangements in such transactions but involve contractual obligations between the parties.

Stakeholder Impact

Shareholders: The merger and increased ownership by Fairmount may lead to strategic shifts that could impact shareholder value. The dual-class board structure may create differing interests between preferred and common shareholders.
Management and Employees: Potential changes in strategic direction or operational focus due to the increased influence of a major investor and board changes.
Creditors: The financial health and strategic direction of the combined entity will impact creditors. The substantial financing and merger indicate ongoing operations and potential for growth.

Next Steps

The Reporting Persons may seek to influence management or the board of directors of Korsana Biosciences.
The company is required to prepare and file a resale registration statement with the SEC within 30 calendar days following the closing of the Merger, as per the Registration Rights Agreement.
The lock-up agreements expire 180 days after the First Effective Time (September 8, 2026), after which restricted securities may be sold.

Key Dates

Date	Description
2024-11-01	Pre-Merger Korsana issued and sold Series Seed Preferred Stock to Fund II.
2025-09-01	Pre-Merger Korsana issued additional Series Seed Preferred Stock and Series A Preferred Stock to Fund II.
2026-04-01	Agreement and Plan of Merger and Reorganization entered into.
2026-04-17	Merger Agreement was amended.
2026-04-20	Registration Statement on Form S-4 filed.
2026-09-08	Merger completed; First Merger Effective Time.
2026-09-08	Company's aggregate outstanding shares as of this date used for ownership percentage calculation.
2026-09-11	Filing date of the Schedule 13D.

Recommendation

hold

The filing indicates a significant investment by Fairmount Funds Management, suggesting confidence in Korsana Biosciences' future. However, the 19.99% ownership cap, beneficial ownership limitations on convertible securities, and the 180-day lock-up period introduce complexities and potential near-term restrictions. While the strategic merger and financing are positive, the lack of detailed operational or financial performance data in this specific filing warrants a 'hold' recommendation pending further information on the combined entity's execution and market performance.

Keywords

Korsana Biosciences, Fairmount Funds Management, Schedule 13D, Merger, Beneficial Ownership, Preferred Stock, Warrants, Investment Management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.